We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will J&J ETFs Suffer on Latest COVID-19 Vaccine Updates?
Read MoreHide Full Article
The coronavirus outbreak continues to worsen as infection cases are rising globally. Recently, Europe crossed the grim milestone of one million coronavirus-related deaths, according to the World Health Organization (WHO). Brazil and China are also facing a severe rise in the daily number of coronavirus cases.
Heightening worries amid this situation, the latest update regarding Johnson & Johnson’s (JNJ - Free Report) coronavirus vaccine is a little depressing. Going by a CNN report, the Centers for Disease Control and Prevention and the FDA recommended an immediate pause on the use of Johnson & Johnson's COVID- 19 vaccine over reports of a "rare and severe type of blood clot" in six out of millions vaccinated.
Notably, the six reported cases fall under the umbrella of more than 6.8 million doses of the Johnson & Johnson vaccine provided in the United States. Going on, the report highlighted that six women between the ages of 18 and 48 saw unusual clots with symptoms appearing six to 13 days after vaccination.
J&J’s single-shot COVID-19 vaccine is presently approved for emergency use in the United States and was granted Conditional Marketing Authorization (CMA) by the European Commission last month. However, the vaccine has not yet been rolled out in European countries.
Moving on, recently the European Medicines Agency (“EMA”) safety committee, Pharmacovigilance Risk Assessment Committee (“PRAC”), started a review to evaluate reports of blood clots in some people who had taken the J&J one-shot COVID-19 vaccine.
Markedly, the EMA’s report mentioned that four cases of rare clots accompanied by low blood platelets have been identified after vaccination with J&J’s vaccine. One of the cases was fatal. Though such blood clot reports increase safety issues, a causal link between J&J’s vaccine and these rare events has not been established. PRAC is analyzing the cases and will give its decision of whether regulatory action is required. J&J is the second company whose COVID-19 vaccine is being studied for rare blood clot events.
JNJ ETFs That Can Suffer
The worsening coronavirus crisis has increased desperation among investors over the accelerated distribution of the coronavirus vaccine to develop herd immunity. In such a scenario, any progress or failure in coronavirus vaccine is going to affect investors’ opinions. Thus, let’s take a look at ETFs that can be affected from the recent development:
This ETF provides exposure to 45 companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. Of these, Johnson & Johnson takes the top spot, accounting for about 22.6% share. The product has charges 42 bps in fees (read: ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update).
The Health Care Select Sector SPDR Fund (XLV - Free Report)
The most-popular healthcare ETF, XLV, follows the Health Care Select Sector Index. Expense ratio comes in at 0.12%. In total, the fund holds 63 securities in its basket, with JNJ taking the top spot, accounting for 9.5% of the assets (read: 4 Sector ETFs to Watch for Gains in Q2).
iShares Evolved U.S. Innovative Healthcare ETF
This actively-managed ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector. Holding 251 stocks in its basket, JNJ is the top firm with a 9.8% allocation. The product charges 18 bps in annual fees (read: ETFs to Tap Amgen's Drive for Cancer Deal).
This fund offers exposure to 126 securities by tracking the Dow Jones U.S. Health Care Index. Here again, Johnson & Johnson dominates the fund’s returns with 8.5% of the total assets. The product charges 43 bps in annual fees.
This ETF tracks the Nasdaq US Smart Pharmaceuticals Index and holds 30 stocks in its basket. Of these, Johnson & Johnson occupies the third position with an 8% allocation. It charges 60 bps in annual fees.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will J&J ETFs Suffer on Latest COVID-19 Vaccine Updates?
The coronavirus outbreak continues to worsen as infection cases are rising globally. Recently, Europe crossed the grim milestone of one million coronavirus-related deaths, according to the World Health Organization (WHO). Brazil and China are also facing a severe rise in the daily number of coronavirus cases.
Heightening worries amid this situation, the latest update regarding Johnson & Johnson’s (JNJ - Free Report) coronavirus vaccine is a little depressing. Going by a CNN report, the Centers for Disease Control and Prevention and the FDA recommended an immediate pause on the use of Johnson & Johnson's COVID- 19 vaccine over reports of a "rare and severe type of blood clot" in six out of millions vaccinated.
Notably, the six reported cases fall under the umbrella of more than 6.8 million doses of the Johnson & Johnson vaccine provided in the United States. Going on, the report highlighted that six women between the ages of 18 and 48 saw unusual clots with symptoms appearing six to 13 days after vaccination.
J&J’s single-shot COVID-19 vaccine is presently approved for emergency use in the United States and was granted Conditional Marketing Authorization (CMA) by the European Commission last month. However, the vaccine has not yet been rolled out in European countries.
Moving on, recently the European Medicines Agency (“EMA”) safety committee, Pharmacovigilance Risk Assessment Committee (“PRAC”), started a review to evaluate reports of blood clots in some people who had taken the J&J one-shot COVID-19 vaccine.
Markedly, the EMA’s report mentioned that four cases of rare clots accompanied by low blood platelets have been identified after vaccination with J&J’s vaccine. One of the cases was fatal. Though such blood clot reports increase safety issues, a causal link between J&J’s vaccine and these rare events has not been established. PRAC is analyzing the cases and will give its decision of whether regulatory action is required. J&J is the second company whose COVID-19 vaccine is being studied for rare blood clot events.
JNJ ETFs That Can Suffer
The worsening coronavirus crisis has increased desperation among investors over the accelerated distribution of the coronavirus vaccine to develop herd immunity. In such a scenario, any progress or failure in coronavirus vaccine is going to affect investors’ opinions. Thus, let’s take a look at ETFs that can be affected from the recent development:
iShares U.S. Pharmaceuticals ETF (IHE - Free Report)
This ETF provides exposure to 45 companies that manufacture prescription or over-the-counter drugs or vaccines by tracking the Dow Jones U.S. Select Pharmaceuticals Index. Of these, Johnson & Johnson takes the top spot, accounting for about 22.6% share. The product has charges 42 bps in fees (read: ETFs to Shine on Pfizer's Impressive COVID-19 Vaccine Update).
The Health Care Select Sector SPDR Fund (XLV - Free Report)
The most-popular healthcare ETF, XLV, follows the Health Care Select Sector Index. Expense ratio comes in at 0.12%. In total, the fund holds 63 securities in its basket, with JNJ taking the top spot, accounting for 9.5% of the assets (read: 4 Sector ETFs to Watch for Gains in Q2).
iShares Evolved U.S. Innovative Healthcare ETF
This actively-managed ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector. Holding 251 stocks in its basket, JNJ is the top firm with a 9.8% allocation. The product charges 18 bps in annual fees (read: ETFs to Tap Amgen's Drive for Cancer Deal).
iShares U.S. Healthcare ETF (IYH - Free Report)
This fund offers exposure to 126 securities by tracking the Dow Jones U.S. Health Care Index. Here again, Johnson & Johnson dominates the fund’s returns with 8.5% of the total assets. The product charges 43 bps in annual fees.
First Trust Nasdaq Pharmaceuticals ETF (FTXH - Free Report)
This ETF tracks the Nasdaq US Smart Pharmaceuticals Index and holds 30 stocks in its basket. Of these, Johnson & Johnson occupies the third position with an 8% allocation. It charges 60 bps in annual fees.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>